Cover Image
Market Research Report

EUROPE DRUG DISCOVERY MARKET FORECAST 2018-2026

Published by Inkwood Research Product code 609208
Published Content info 88 Pages
Delivery time: 1-2 business days
Price
Back to Top
EUROPE DRUG DISCOVERY MARKET FORECAST 2018-2026
Published: March 2, 2018 Content info: 88 Pages
Description

KEY FINDINGS

The European drug discovery market is set to grow at an impresive rate over the forecast period of 2018-2026. This essentail healthcare market is anticipated to rise at with a 9.33% CAGR.

MARKET INSIGHTS

The European healthcare market is equipped with comprehensive and updated technology. Also, the healthcare spending of European countries is increasing considerably. The U.K drug discovery market accounted for the most significant revenue share in 2017. Other significant contributors included Germany, France, Spain, Italy and rest of Europe. Implementation of drug discovery programs across these regions is boosting the market demand. However, stringent government regulations delaying the processes for product launches could significantly restrain the market growth.

COMPETITIVE INSIGHTS

Boehringer Ingelheim, GlaxoSmithKline Llc, Bayer Ag, F. Hoffmann-La Roche Ltd, Sanofi, Eli Lily, Pfizer Inc, AstraZeneca Plc and Merck & Co. Inc are few of the established players in this market.

Table of Contents
Product Code: 13804

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. HIGH PREVALENCE RATE OF MAJOR HEALTH DISORDERS
    • 3.2.2. IMPLEMENTATION OF DRUG DISCOVERY PROGRAMS

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. AGING POPULATION
    • 4.1.2. BRANDED DRUGS OUTPERFORMING DUE TO HIGH COST AS COMPARED TO GENERIC DRUGS
    • 4.1.3. SPENDING ON HEALTHCARE HAS INCREASED
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. GOVERNMENT REGULATIONS DELAYING THE PROCESSES
    • 4.2.2. DELAY IN PRODUCT LAUNCHES
    • 4.2.3. POOR ACCESS TO HEALTHCARE SERVICES IN DEVELOPING MARKETS
    • 4.2.4. MARKET IS SHIFTING FROM BRANDED TO GENERIC DRUGS
  • 4.3. MARKET OPPORTUNITIES
    • 4.3.1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES

5. MARKET SEGMENTATION

  • 5.1. MARKET BY TECHNOLOGY 2018-2026
    • 5.1.1. QPCR
    • 5.1.2. DNA MICROARRAYS
    • 5.1.3. PROTEIN MICROARRAYS
    • 5.1.4. HIGH-THROUGHPUT SCREENING
    • 5.1.5. MASS SPECTROMETRY
    • 5.1.6. GEL ELECTROPHORESIS
    • 5.1.7. CHROMATOGRAPHY
    • 5.1.8. PROTEIN AND NUCLEIC ACID ISOLATION
    • 5.1.9. OTHER TECHNOLOGIES

6. KEY ANALYTICS

  • 6.1. PORTER'S FIVE FORCES ANALYSIS
    • 6.1.1. THREATS OF NEW ENTRANTS(LOW)
    • 6.1.2. COMPETITIVE RIVALRY (HIGH)
    • 6.1.3. BARGAINING POWER OF BUYERS (MEDIUM)
    • 6.1.4. BARGAINING POWER OF SUPPLIERS (LOW)
    • 6.1.5. THREAT OF SUBSTITUTE PRODUCTS (HIGH)
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. KEY EXCERPTS OF THE STUDY
    • 6.3.1. RELAXATION IN THE REGULATIONS BY THE GOVERNMENT WHICH STOPS RESEARCHERS FROM DOING RESEARCH
    • 6.3.2. MARKET LEADERS SHOULD OPEN UP THEIR BRANCHES AND RESEARCH LABS IN EMERGING MARKETS.
  • 6.4. PESTLE ANALYSIS
  • 6.5. OPPORTUNITY MATRIX

7. GEOGRAPHICAL ANALYSIS

  • 7.1. EUROPE
    • 7.1.1. UNITED KINGDOM (UK)
    • 7.1.2. FRANCE
    • 7.1.3. GERMANY
    • 7.1.4. SPAIN
    • 7.1.5. ITALY
    • 7.1.6. REST OF EUROPE (ROE)

8. COMPANY PROFILES

  • 8.1. ASTRAZENECA PLC
    • 8.1.1. COMPANY OVERVIEW
    • 8.1.2. PRODUCT PORTFOLIO
    • 8.1.3. SWOT ANALYSIS
    • 8.1.4. STRATEGIC INITIATIVES
  • 8.2. BAYER AG
    • 8.2.1. COMPANY OVERVIEW
    • 8.2.2. PRODUCT PORTFOLIO
    • 8.2.3. SWOT ANALYSIS
    • 8.2.4. STRATEGIC INITIATIVES
  • 8.3. BOEHRINGER INGELHEIM
    • 8.3.1. COMPANY OVERVIEW
    • 8.3.2. PRODUCT PORTFOLIO
    • 8.3.3. SWOT ANALYSIS
  • 8.4. ELI LILY
    • 8.4.1. COMPANY OVERVIEW
    • 8.4.2. PRODUCT PORTFOLIO
    • 8.4.3. SWOT ANALYSIS
    • 8.4.4. STRATEGIC INITIATIVES
  • 8.5. F. HOFFMANN-LA ROCHE LTD
    • 8.5.1. COMPANY OVERVIEW
    • 8.5.2. PRODUCT PORTFOLIO
    • 8.5.3. SWOT ANALYSIS
    • 8.5.4. STRATEGIC INITIATIVES
  • 8.6. GLAXOSMITHKLINE LLC
    • 8.6.1. COMPANY OVERVIEW
    • 8.6.2. PRODUCT PORTFOLIO
    • 8.6.3. SWOT ANALYSIS
    • 8.6.4. STRATEGIC INITIATIVES
  • 8.7. JOHNSON AND JOHNSON
    • 8.7.1. COMPANY OVERVIEW
    • 8.7.2. PRODUCT PORTFOLIO
    • 8.7.3. SWOT ANALYSIS
    • 8.7.4. STRATEGIC INITIATIVES
  • 8.8. MERCK & CO. INC.
    • 8.8.1. COMPANY OVERVIEW
    • 8.8.2. PRODUCT PORTFOLIO
    • 8.8.3. SWOT ANALYSIS
    • 8.8.4. STRATEGIC INITIATIVES
  • 8.9. PFIZER, INC.
    • 8.9.1. COMPANY OVERVIEW
    • 8.9.2. SWOT ANALYSIS
    • 8.9.3. STRATEGIC INITIATIVES
  • 8.10. SANOFI
    • 8.10.1. COMPANY OVERVIEW
    • 8.10.2. PRODUCT PORTFOLIO
    • 8.10.3. SWOT ANALYSIS
    • 8.10.4. STRATEGIC INITIATIVES

TABLE LIST

  • TABLE 1 EUROPE DRUG DISCOVERY MARKET 2018-2026 (IN $MILLION)
  • TABLE 2 EUROPE DRUG DISCOVERY MARKET, BY TECHNOLOGY 2018-2026
  • TABLE 3 EUROPE DRUG DISCOVERY MARKET IN QPCR 2018-2026 (IN $MILLION)
  • TABLE 4 EUROPE DRUG DISCOVERY MARKET IN DNA MICROARRAYS 2018-2026 (IN $MILLION)
  • TABLE 5 EUROPE DRUG DISCOVERY MARKET IN PROTEIN MICROARRAYS, 2018-2026 (IN $MILLION)
  • TABLE 6 EUROPE DRUG DISCOVERY MARKET IN HIGH THROUGHPUT SCREENING, 2018-2026 (IN $MILLION)
  • TABLE 7 EUROPE DRUG DISCOVERY MARKET IN MASS SPECTROMETRY, 2018-2026 (IN $MILLION)
  • TABLE 8 EUROPE DRUG DISCOVERY MARKET IN GEL ELECTROPHORESIS, 2018-2026, (IN $MILLION)
  • TABLE 9 EUROPE DRUG DISCOVERY MARKET IN CHROMATOGRAPHY, 2018-2026 (IN $MILLION)
  • TABLE 10 EUROPE DRUG DISCOVERY MARKET IN PROTEIN AND NUCLEIC ACID ISOLATION, 2018-2026 (IN $MILLION)
  • TABLE 11 EUROPE DRUG DISCOVERY MARKET IN OTHER TECHNOLOGIES MARKET, 2018-2026 (IN $MILLION)
  • TABLE 12 EUROPE DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE LIST
  • FIGURE 1 EUROPE DRUG DISCOVERY MARKET 2018-2026 (IN $MILLION)
  • FIGURE 2 EUROPE DRUG DISCOVERY MARKET IN QPCR 2018-2026 (IN $MILLION)
  • FIGURE 3 EUROPE DRUG DISCOVERY MARKET IN DNA MICROARRAYS 2018-2026 (IN $MILLION)
  • FIGURE 4 EUROPE DRUG DISCOVERY MARKET IN PROTEIN MICROARRAYS 2018-2026 (IN $MILLION)
  • FIGURE 5 EUROPE DRUG DISCOVERY MARKET IN HIGH THROUGHPUT SCREENING 2018-2026 (IN $MILLION)
  • FIGURE 6 EUROPE DRUG DISCOVERY MARKET IN MASS SPECTROMETRY 2018-2026 (IN $MILLION)
  • FIGURE 7 EUROPE DRUG DISCOVERY MARKET IN GEL ELECTROPHORESIS 2018-2026 (IN $MILLION)
  • FIGURE 8 EUROPE DRUG DISCOVERY MARKET IN CHROMATOGRAPHY 2018-2026 (IN $MILLION)
  • FIGURE 9 EUROPE DRUG DISCOVERY MARKET IN PROTEIN AND NUCLEIC ACID ISOLATION 2018-2026 (IN $MILLION)
  • FIGURE 10 EUROPE DRUG DISCOVERY MARKET IN OTHER TECHNOLOGIES 2018-2026 (IN $MILLION)
  • FIGURE 11 EUROPE DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 12 UNITED KINGDOM DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 13 FRANCE DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 14 GERMAN DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 15 SPAIN DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 16 ITALY DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 17 REST OF EUROPE (ROE) DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
Back to Top